KR20150028761A - 섬유증 치료용 안지오텐신 - Google Patents

섬유증 치료용 안지오텐신 Download PDF

Info

Publication number
KR20150028761A
KR20150028761A KR20147019878A KR20147019878A KR20150028761A KR 20150028761 A KR20150028761 A KR 20150028761A KR 20147019878 A KR20147019878 A KR 20147019878A KR 20147019878 A KR20147019878 A KR 20147019878A KR 20150028761 A KR20150028761 A KR 20150028761A
Authority
KR
South Korea
Prior art keywords
angiotensin
fibrosis
peptide
amino acid
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20147019878A
Other languages
English (en)
Korean (ko)
Inventor
폴 베링거
리차드 프랭클린
Original Assignee
타릭스 파마슈티컬스 엘티디.
유니버시티 오브 써던 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타릭스 파마슈티컬스 엘티디., 유니버시티 오브 써던 캘리포니아 filed Critical 타릭스 파마슈티컬스 엘티디.
Publication of KR20150028761A publication Critical patent/KR20150028761A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Reinforced Plastic Materials (AREA)
KR20147019878A 2011-12-16 2012-12-14 섬유증 치료용 안지오텐신 Withdrawn KR20150028761A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161576673P 2011-12-16 2011-12-16
US61/576,673 2011-12-16
US201161579936P 2011-12-23 2011-12-23
US61/579,936 2011-12-23
PCT/US2012/069930 WO2013090833A1 (en) 2011-12-16 2012-12-14 Angiotensins for treatment of fibrosis

Publications (1)

Publication Number Publication Date
KR20150028761A true KR20150028761A (ko) 2015-03-16

Family

ID=48613248

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147019878A Withdrawn KR20150028761A (ko) 2011-12-16 2012-12-14 섬유증 치료용 안지오텐신

Country Status (9)

Country Link
US (2) US20150057216A1 (https=)
EP (1) EP2790716A4 (https=)
JP (1) JP2015504870A (https=)
KR (1) KR20150028761A (https=)
CN (1) CN104302305A (https=)
AU (1) AU2012351939A1 (https=)
BR (1) BR112014014674A2 (https=)
CA (1) CA2859573A1 (https=)
WO (1) WO2013090833A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102743940B1 (ko) 2023-10-06 2024-12-19 엠브릭스 주식회사 안지오텐신 전환효소 2 및 Fc 절편을 포함하는 나노디스크 및 이의 용도

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
RU2015147241A (ru) * 2013-05-24 2017-06-29 Терикс Фармасьютикалз Лтд. Пептиды ангиотензина при лечении синдрома марфана и связанных с ним нарушений
JP6254692B2 (ja) * 2013-07-03 2017-12-27 ジ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ 認知機能不全を治療するための方法
AU2015258997B2 (en) * 2014-05-16 2019-04-18 Ultrast, Inc. Phase-shifting formulations
JP6666899B2 (ja) 2014-07-21 2020-03-18 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
JP2018527330A (ja) 2015-07-30 2018-09-20 モナシュ ユニバーシティー 線維症の処置
WO2017066552A1 (en) 2015-10-14 2017-04-20 Tarix Pharmaceuticals Ltd. Methods and compositions for the treatment of epidermolysis bullosa
WO2017218623A1 (en) * 2016-06-14 2017-12-21 Tarix Orphan Llc Methods and compositions for the treatment of epidermolysis bullosa
WO2019014710A1 (en) * 2017-07-17 2019-01-24 Monash University ANGIOTENSIN RECEPTOR AGONISTS AND USES THEREOF
GB201913603D0 (en) 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
WO2021164723A1 (en) * 2020-02-20 2021-08-26 Lee Sheau Long Ginsenoside m1 as a modulator of angiotensin regulating enzymes and its use for treating diseases or conditions including symptoms caused by coronavirus
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
EP4085921A1 (en) * 2021-05-04 2022-11-09 CU-Pharmaceuticals UG Angiotensin-(1-7) in the treatment of sars-cov related diseases
EP4085896A1 (en) * 2021-05-04 2022-11-09 CU-Pharmaceuticals UG Pharmaceutical angiotensin-(1-7) compositions in the treatment of (sars)-cov- or (sars)-cov-2-infection related diseases
CA3249539A1 (en) 2022-02-10 2023-08-17 Vicore Pharma Ab USE OF BULOXIBUTID FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
GB202201723D0 (en) 2022-02-10 2022-03-30 Vicore Pharma Ab New use
WO2025050228A1 (es) * 2023-09-08 2025-03-13 Pontificia Universidad Católica De Chile Composición farmacéutica que comprende un péptido o una combinación de péptidos agonistas de los receptores mas, at1 y at2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69824445T2 (de) * 1997-12-12 2005-06-30 University Of Southern California, Los Angeles Zusammensetzungen zur wundheilung
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
US7064127B2 (en) * 2003-12-19 2006-06-20 Mount Sinai School Of Medicine Of New York University Treatment of hepatic fibrosis with imatinib mesylate
EP2163259B1 (en) * 2008-09-12 2012-06-13 Charité-Universitätsmedizin Berlin (Charité) Use of an Ang-(1-7) receptor agonist in acute lung injury

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102743940B1 (ko) 2023-10-06 2024-12-19 엠브릭스 주식회사 안지오텐신 전환효소 2 및 Fc 절편을 포함하는 나노디스크 및 이의 용도
KR20250051534A (ko) 2023-10-06 2025-04-17 엠브릭스 주식회사 Fc 절편이 융합된 안지오텐신 전환효소 2를 포함하는 나노디스크 및 이의 용도

Also Published As

Publication number Publication date
EP2790716A1 (en) 2014-10-22
BR112014014674A2 (pt) 2017-06-13
WO2013090833A1 (en) 2013-06-20
US20150057216A1 (en) 2015-02-26
EP2790716A4 (en) 2015-06-10
WO2013090833A8 (en) 2014-07-17
CN104302305A (zh) 2015-01-21
US20160074466A1 (en) 2016-03-17
CA2859573A1 (en) 2013-06-20
JP2015504870A (ja) 2015-02-16
AU2012351939A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
KR20150028761A (ko) 섬유증 치료용 안지오텐신
US20140112947A1 (en) Polypeptide Inhibitors of HSP27 Kinase and Uses Therefor
US20130210726A1 (en) Compositions and methods for treatment of peripheral vascular disease
AU2019366366B2 (en) Therapeutic combinations of TDFRPs and additional agents and methods of use
US8748575B2 (en) Therapeutic peptides
CN102869677A (zh) 胃肠病症的治疗
CN116196388A (zh) 用于预防和治疗杜氏肌肉萎缩症的方法和组合物
RS57914B1 (sr) Antimikrobni peptid i njegove primene
US20180050079A1 (en) Angiotensin peptides in treating marfan syndrome and related disorders
US20230110554A1 (en) Methods and compositions for treatment of coronavirus infection
KR20150065736A (ko) 안지오텐신의 경구 제형
US8557958B1 (en) Compositions and methods for treatment of diabetes
US20160296591A1 (en) Compositions and methods for treatment of bdnf-related conditions
US20240002437A1 (en) Compositions and methods of treating inflammatory lung diseases
WO2015057403A2 (en) Compositions and methods for treatment of inflammatory bowel disease
CN110741015B (zh) 用于治疗和/或预防致病性真菌感染和维持微生物群系共生的组合物和方法
WO2025122594A1 (en) Improved methods and compositions for the treatment of pemphigus or pemphigoid disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140716

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid